Reported data from cohort 1 of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up Quality of life outcomes measured by Cystic. | June 9, 2023
Interim data to be presented in an oral presentation by Dr. Jennifer L. Taylor-Cousar, MD, MSCS at the 2023 ECFS Annual Meeting in Vienna, Austria on Thursday, June 8, 2023 at 5:00 p.m. CET Company to. | May 24, 2023
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual MeetingOn track for completion of enrollment. | May 10, 2023
Underwriters’ full exercise of option brings gross proceeds to $138.0 millionEMERYVILLE, Calif., May 09, 2023 4D Molecular Therapeutics, Inc. , a clinical-stage biotherapeutics company. | May 9, 2023
EMERYVILLE, Calif., May 08, 2023 4D Molecular Therapeutics, Inc. , a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large. | May 8, 2023